Dr. Andrew Chan joined Genentech, Inc in 2001 as Senior Director of the Departments of Immunology and Antibody Technologies, named VP and SVP of Research-Immunology in 2003 and 2007, respectively, and appointed SVP-Research Biology in 2010 where he oversees biological research at Genentech. He is also Associate Professor of Medicine at UCSF.
Chan received his BA and MS degrees in Chemistry at Northwestern University, MD and PhD degrees from Washington University (WUSM) and completed his internal medicine residency at Barnes Hospital and rheumatology fellowship at UCSF. He joined the faculty at WUSM in the Departments of Medicine and Pathology and was a member of the Howard Hughes Medical Institute. His research focuses on signaling mechanisms of immune cells, immunobiology of immunodeficiencies and autoimmunity, human disease heterogeneity and mechanisms of immunomodulatory therapies. Chan is a co-inventor of ocrelizumab approved for the treatment of multiple sclerosis.
Chan serves on the National Council of WUSM, National Research Advisory Council for WU, Russell/Engleman Arthritis Center Board, Medical Scientific Advisory Committee of the Arthritis Foundation and Chemistry Life Processes Institute at Northwestern University. He is a member of the American Association of Physicians, American Society for Clinical Investigation, Henry Kunkel Society and a Pew Scholar.